AbbVie reported Q3 2024 revenues of $14.46 billion, up 3.8% year-over-year, driven by strong performance across key portfolios. Immunology revenues grew 3.9% to $7.05 billion, with Skyrizi and Rinvoq showing robust growth of 50.8% and 45.3% respectively, offsetting Humira's 37.2% decline. Neuroscience revenues increased 15.6% to $2.36 billion, led by Vraylar and Botox Therapeutic.The company raised its full-year 2024 adjusted EPS guidance to $10.90-$10.94 from $10.67-$10.87, reflecting strong business momentum. Additionally, AbbVie announced a 5.8% increase in quarterly dividend to $1.64 per share, marking its 310% dividend growth since 2013.AbbVie completed the acquisition of Cerevel Therapeutics, strengthening its neuroscience portfolio with complementary pipeline assets. The company also reported positive Phase 3 results for tavapadon in early Parkinson's disease and received FDA approval for Vyalev as the first subcutaneous 24-hour levodopa-based therapy for advanced Parkinson's disease.

AbbVie reported Q3 2024 revenues of $14.46 billion, up 3.8% year-over-year, driven by strong performance across key portfolios. Immunology revenues grew 3.9% to $7.05 billion, with Skyrizi and Rinvoq showing robust growth of 50.8% and 45.3% respectively, offsetting Humira's 37.2% decline. Neuroscience revenues increased 15.6% to $2.36 billion, led by Vraylar and Botox Therapeutic.The company raised its full-year 2024 adjusted EPS guidance to $10.90-$10.94 from $10.67-$10.87, reflecting strong business momentum. Additionally, AbbVie announced a 5.8% increase in quarterly dividend to $1.64 per share, marking its 310% dividend growth since 2013.AbbVie completed the acquisition of Cerevel Therapeutics, strengthening its neuroscience portfolio with complementary pipeline assets. The company also reported positive Phase 3 results for tavapadon in early Parkinson's disease and received FDA approval for Vyalev as the first subcutaneous 24-hour levodopa-based therapy for advanced Parkinson's disease.